Loading stock data…
GCTK
$0.80-0.05 (-6.31%)
Market ClosedLast close May 1
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GlucoTrack, Inc. in the Healthcare sector is trading at $0.80. The stock is currently near its 52-week low of $0.62, remaining 81.1% below its 200-day moving average. Technical signals show neutral RSI of 44 and bullish MACD crossover, explaining why GCTK maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.80
Potential Upside
5%
Whystock Fair Value$0.84
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack, a non-invasive glucose monitoring dev...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.40M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.61
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-164.57%
Volume
Today's trading volume
1.25M
Recent News
Glucotrack Shows Long-Term Accuracy of Implantable Glucose Monitor
By Daniella Parra Glucotrack, Inc. (Nasdaq: GCTK) shared a study highlighting the long-term accuracy of its implantable blood glucose monitoring system as it moves closer to FDA clinical development and eventual commercialization, it said. The results also align with earlier human trials, which showed similar accuracy and a high data capture rate without serious adverse […]
Study Supports GlucoTrack’s Blood Glucose Monitoring Implant
By Karen Roman GlucoTrack, Inc. (Nasdaq: GCTK) said a peer-reviewed study published in the Institute of Electrical and Electronics Engineers Sensors Journal supported the feasibility of long-life implantable continuous glucose monitors like the devices the company develops. The article came out on April 7, 2026, and is the result of a partnership between GlucoTrack and […]
Glucotrack to File for FDA Exemption Based on 2025 Milestones
By Karen Roman GlucoTrack, Inc. (Nasdaq: GCTK) said it will request an Investigational Device Exemption (IDE) from the FDA for its continuous blood glucose monitoring technology. This submission follows the completion of clinical trials in Brazil and Australia, and is set to be completed during the second quarter of 2026, the company stated. “With trial […]
BC-Most Active Stocks
Megan Holdings Ltd. 7,893,938 0.2401
Glucotrack Announces 3 New Patents to Monitor Blood Glucose
By Karen Roman GlucoTrack, Inc. (Nasdaq: GCTK) said the U.S. Patent and Trademark Office issued three patents for its continuous blood glucose monitoring platform as the company moves toward commercializing it. The three patents protect key technologies related to proprietary sensor chemistry, intravascular lead design, and low-power electronics, the company stated. “Securing our intellectual property […]